THYROCARE2024-01-012024-03-31 THYROCARE2024-01-012024-03-31 THYROCARE2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member THYROCARE2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member THYROCARE2024-03-31 THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue01Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue02Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue03Member THYROCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue01Member THYROCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue02Member THYROCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue03Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults01Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults02Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults03Member THYROCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults01Member THYROCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults02Member THYROCARE2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults03Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets01Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets02Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets03Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member THYROCARE2024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member THYROCARE2024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member THYROCARE2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities03Member THYROCARE2024-03-31in-bse-fin:OneReportableSegmentLiabilities03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539871 THYROCARE NA Thyrocare Technologies Limited Equity 2023-04-01 2024-03-31 2024-05-14 2024-05-07 INR Crores Yearly 14:20:00 15:20:00 2024-05-14 2024-05-14 true Cash Flow Indirect Declaration of unmodified opinion Multi segment 2024-01-01 2024-03-31 Audited Consolidated 1542500000.00 34900000.00 1577400000.00 461200000.00 10600000.00 -6100000.00 265700000.00 11200000.00 130600000.00 473000000.00 1346200000.00 231200000.00 -2200000.00 229000000.00 71200000.00 -14000000.00 57200000.00 0.00 171800000.00 0.00 0.00 0.00 0.00 171800000.00 600000.00 172400000.00 177900000.00 -6000000.00 172600000.00 -200000.00 529500000.00 10 3.54 3.54 0.00 0.00 3.54 3.54 Based on the management approach as defined in IndAS 108 - Operating Segments, the Chief Operating Decision Maker evaluates the Group's Performance. The Company has identified business segments as its primary segments. The Company recognizes its diagnostic testing services activity and imaging services including manufacturing of radiopharmaceuticals activity as its primary business segments. Diagnostic testing services operations predominantly consists of providing laboratory testing services to its customers. Imaging services segment represents PET-CT scan and sale of radio pharmaceuticals used in imaging services. Others represents trading and other related business activities. The accounting principles used in the preparation of the financial statements are consistently applied to record revenue and expenditure in individual segments. The above consolidated audited financial results of the Company were reviewed and recommended by the Audit Committee on 14 May 2024 and subsequently approved by the Board of Directors at its meeting held on 14 May 2024. The statutory auditors of the Company have expressed an unmodified opinion on the consolidated audited financial results for the year ended March 31, 2024. The figures for the quarter ended March 31, 2024 and March 31, 2023 are the balancing figures between audited figures in respect of the full financial year and the limited reviewed year to date figures up to the quarters ended December 31, 2023and December 31, 2022 respectively. These audited consolidated financial results have been prepared in compliance with Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable. The consolidated audited financial results are available on the website of the Company (www.thyrocare.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com). During the year ended March 31, 2024 the Company has allotted 22,633 equity shares of Rs. 10 each fully paid-up, respectively, on exercise of stock options by employees in accordance with the Company's stock option scheme. Also, during the quarter ended and year ended 31 March 2024, the company has forfeited 8,729 equity stock options and 32,666 equity stock options, respectively granted to employees under employees stock option schemes but not vested on account of discontinuance of services of these employees, which has been added back to the pool and the same would be available for subsequent distribution subject to statutory rules and regulations, as applicable. In accordance with Ind AS 108 'Operating Segments', segment information has been given in the consolidated financial results of the Company. Previous periods'/years' figures have been regrouped/ reclassified wherever required, to make them comparable with the figure for the current period/year. Multi segment 2023-04-01 2024-03-31 Audited Consolidated 5718800000.00 93700000.00 5812500000.00 1645100000.00 24700000.00 -2800000.00 1078600000.00 42000000.00 470100000.00 1598900000.00 4856600000.00 955900000.00 0.00 955900000.00 301200000.00 -36300000.00 264900000.00 0.00 691000000.00 0.00 0.00 0.00 3900000.00 694900000.00 2900000.00 697800000.00 707600000.00 -12700000.00 710500000.00 -12700000.00 529500000.00 10 0.00 13.42 13.40 0.00 0.00 13.42 13.40 other expenses 473000000.00 other expenses 1598900000.00 8600000.00 1684400000.00 25500000.00 0.00 1040300000.00 334200000.00 0.00 0.00 256200000.00 0.00 0.00 0.00 52200000.00 52200000.00 148200000.00 112800000.00 3653800000.00 475200000.00 1367500000.00 434700000.00 93000000.00 305900000.00 0.00 33100000.00 2234200000.00 0.00 75600000.00 2785000000.00 0.00 0.00 6438800000.00 529500000.00 4738200000.00 5267700000.00 5276300000.00 109100000.00 0.00 118000000.00 227100000.00 30600000.00 0.00 0.00 0.00 257700000.00 106900000.00 401100000.00 264200000.00 772200000.00 91500000.00 28200000.00 12900000.00 0.00 904800000.00 0.00 0.00 1162500000.00 6438800000.00 Diagnostic Testing Services 1411100000.00 Imaging Services 127600000.00 Others 3800000.00 Diagnostic Testing Services 5222280000.00 Imaging Services 476050000.00 Others 20470000.00 1542500000.00 5718800000.00 0.00 0.00 1542500000.00 5718800000.00 Diagnostic Testing Services 189000000.00 Imaging Services -22900000.00 Others -700000.00 Diagnostic Testing Services 909500000.00 Imaging Services -45900000.00 Others -1500000.00 165400000.00 862100000.00 0.00 0.00 65700000.00 93700000.00 99700000.00 768400000.00 Diagnostic Testing Services 4217700000.00 Imaging Services 1816300000.00 Others 0.00 6034000000.00 404400000.00 6438400000.00 Diagnostic Testing Services 969700000.00 Imaging Services 129500000.00 Others 0.00 1099200000.00 12900000.00 1112100000.00 42000000.00 -198500000.00 328200000.00 0.00 21600000.00 0.00 0.00 0.00 0.00 161200000.00 0.00 3800000.00 9300000.00 470100000.00 0.00 73700000.00 0.00 0.00 0.00 0.00 0.00 9800000.00 0.00 -57900000.00 0.00 0.00 166700000.00 0.00 0.00 1010400000.00 1966300000.00 0.00 0.00 0.00 289900000.00 0.00 1676400000.00 0.00 0.00 0.00 0.00 0.00 35200000.00 0.00 0.00 7200000.00 615900000.00 0.00 79900000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 198900000.00 0.00 0.00 0.00 0.00 0.00 9800000.00 0.00 0.00 0.00 -912900000.00 0.00 0.00 200000.00 0.00 0.00 -12100000.00 0.00 0.00 286200000.00 70200000.00 0.00 57200000.00 952700000.00 66400000.00 0.00 0.00 -848000000.00 -84500000.00 0.00 -84500000.00 177700000.00 93200000.00 -700000.00 -3800000.00 100000.00 900000.00